This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ¿ database) Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease. This randomized Phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Patients will receive infusions or injections of combination chemotherapy on Days 1-3 and 8. They will also receive prednisone by mouth two or three times a day on Days 1-7. Beginning on Day 4, patients will also receive injections of filgrastim once a day (except Day 8) until blood counts return to normal. Treatment may be repeated every 3 weeks for up to two courses. Patients will then be assigned to one of two groups. Patients in Group 1 will receive two additional courses of the initial chemotherapy regimen, followed by either radiation therapy or no further treatment. Patients in Group 2 will be randomly assigned to one of two groups to receive either two courses of another chemotherapy regimen plus two additional courses of the initial chemotherapy regimen, followed by radiation therapy OR two additional courses of the initial chemotherapy regimen followed by radiation therapy. Patients will be evaluated every 3 months for 2 years, every 6 months for 3 years, and once a year thereafter.